C9121 Argatroban Injection HCPCS Reimbursement

HCPCS Level II code C9121 denotes a 5 mg unit of argatroban injection, a parenteral direct thrombin inhibitor used in anticoagulation management. As a drug-specific HCPCS Level II code, C9121 is used when argatroban is billed separately from procedural or facility charges and is relevant across inpatient, outpatient, and infusion settings. Nationally, accurate coding for this medication matters for clinical billing integrity, drug utilization monitoring, and payer reimbursement consistency.

Key payers in the national landscape include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides an overview of how C9121 is applied in claims, typical sites of service, and the clinical context in which argatroban is administered. Readers will find benchmarks and policy-oriented summaries where available, discussion of billing practice considerations for injectable anticoagulants, and notes on coding contexts that affect coverage and reimbursement. Specific modifier, taxonomy, diagnosis, and related-code details are not provided in the input and are noted as unavailable where applicable.

This summary serves clinicians, billing professionals, and policy analysts seeking a concise reference to the clinical meaning and billing context of HCPCS Level II code C9121 for national operational and compliance purposes.

Billing Code Overview

HCPCS Level II code C9121 describes injection, argatroban, per 5 mg. This code represents a billed unit of the anticoagulant argatroban supplied for parenteral administration. The service type is an injectable anticoagulant medication.

The typical site of service for billing HCPCS Level II code C9121 is settings where parenteral anticoagulant therapy is administered and billed separately, such as hospital inpatient and outpatient departments, ambulatory infusion centers, and clinics.

Data not available in the input.

Clinical Context

A typical patient is an adult hospitalized for acute thrombosis or at high risk for heparin-induced thrombocytopenia (HIT) requiring parenteral direct thrombin inhibition. The physician orders C9121 (injection, argatroban, per 5 mg) for continuous intravenous infusion or intermittent dosing during initiation and maintenance of anticoagulation when heparin is contraindicated. The clinical workflow includes: initial assessment of bleeding risk and hepatic function; calculation of weight-based infusion rates; pharmacy preparation of argatroban vial(s) per C9121; nursing administration via infusion pump with frequent activated partial thromboplastin time (aPTT) monitoring; dose titration to therapeutic aPTT range; documentation of indication (for example, suspected or confirmed HIT, or periprocedural anticoagulation in heparin-allergic patients); and coordination of transition to oral anticoagulation if appropriate. Typical sites of service are inpatient hospital units, intensive care units, and procedural suites where systemic anticoagulation is required.

Coding Specifications

Modifier	Description	When to Use
`24`	Unrelated evaluation and management service by the same physician during a postoperative period	Use when an unrelated E/M is performed during a postoperative period in the same encounter as argatroban administration.

Taxonomy Code	Specialty	Notes
`208D00000X`	Hematology	Manages HIT, thrombosis, and anticoagulation strategy involving argatroban.
`207RC0000X`	Internal Medicine	Hospitalists manage inpatient anticoagulation and coordinate argatroban therapy.
`207L00000X`	Anesthesiology	Provides anticoagulation management perioperatively or during procedural anticoagulation.
`207RH0000X`	Critical Care Medicine	Manages argatroban in ICU patients with complex coagulopathy and monitoring needs.
`363L00000X`	Pharmacist	Clinical pharmacists prepare and verify argatroban dosing, infusion, and drug interactions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D69.59`	Other secondary thrombocytopenia	Relevant for suspected heparin-induced thrombocytopenia requiring non-heparin anticoagulation with argatroban.
`D75.82`	Heparin-induced thrombocytopenia (HIT)	Primary indication for argatroban when HIT is confirmed or strongly suspected.
`I82.40`	Acute embolism and thrombosis of unspecified deep veins of lower extremity	Deep venous thrombosis where heparin is contraindicated and argatroban is used as alternative anticoagulation.
`I26.99`	Other pulmonary embolism without acute cor pulmonale	Pulmonary embolism requiring parenteral anticoagulation when heparin cannot be used.
`Z79.01`	Long term (current) use of anticoagulants	Documentation of ongoing anticoagulant therapy; argatroban may be used short term before transition to oral agents.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36556`	Injection of non-chemotherapeutic agent into central venous catheter, access for medication administration	Used when argatroban is administered through a central venous catheter for continuous infusion.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	May be reported for the initial infusion management time when argatroban infusion initiation requires direct patient observation and management.
`96366`	Intravenous infusion, each additional hour (list separately in addition to code for primary infusion)	Used for additional hours of monitored infusion when time-based infusion services are separately reportable.
`36415`	Collection of venous blood by venipuncture	Performed for laboratory monitoring such as aPTT when titrating argatroban dosing.
`85025`	Blood count; complete (CBC) automated and automated differential WBC count	Frequently ordered in anticoagulation monitoring and evaluation of thrombocytopenia associated with HIT.

OpenPayer

Summary & Overview

HCPCS C9121: Argatroban Injection, per 5 mg